Annual report pursuant to Section 13 and 15(d)

Note 15 - Segments - Segment Information (Details)

v3.23.1
Note 15 - Segments - Segment Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax $ 14,645 $ 45,615
Grant and other revenue 51,007 485,898
Revenues, Total 65,652 531,513
Research and development expenses 5,969,774 5,141,910
Cost of revenue 1,941 0
Selling, general and administrative expenses, excluding depreciation and amortization (1) [1] 7,866,007 7,373,061
Adjustments for expired and expiring inventory 183,006 0
Depreciation and amortization (2) [2] 95,819 76,954
Loss from operations (3) [3] (14,050,895) (12,060,412)
Other expense, net (4) [4] (1,126,261) 345,524
Provision for income taxes 0 (16,043)
Net loss (15,177,156) (11,730,931)
United States 4,371,606 6,644,833
Capital expenditures 63,086 25,218
UNITED STATES    
United States 3,817,805 6,433,962
Non-US [Member]    
United States 553,801 210,871
Diagnostics Segment [Member]    
Grant and other revenue 51,007 485,898
Revenues, Total 65,652 531,513
Research and development expenses 5,501,134 4,488,177
Cost of revenue 1,941  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [1] 0 0
Adjustments for expired and expiring inventory 183,006  
Depreciation and amortization (2) [2] 29,387 24,162
Loss from operations (3) [3] (5,649,816) (3,980,826)
Other expense, net (4) [4] 0 0
Provision for income taxes   (5,452)
Net loss (5,649,816) (3,986,278)
Capital expenditures 54,650 0
Diagnostics Segment [Member] | UNITED STATES    
United States 610 107,931
Diagnostics Segment [Member] | Non-US [Member]    
United States 539,188 210,281
Therapeutics Segment [Member]    
Grant and other revenue 0 0
Revenues, Total 0 0
Research and development expenses 468,640 653,733
Cost of revenue 0  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [1] 4,530 4,438
Adjustments for expired and expiring inventory 0  
Depreciation and amortization (2) [2] 0 0
Loss from operations (3) [3] (473,170) (658,171)
Other expense, net (4) [4] 0 0
Provision for income taxes   (901)
Net loss (473,170) (659,072)
Capital expenditures 0 0
Therapeutics Segment [Member] | UNITED STATES    
United States 0 0
Therapeutics Segment [Member] | Non-US [Member]    
United States 0 0
Corporate Segment [Member]    
Grant and other revenue 0 0
Revenues, Total 0 0
Research and development expenses 0 0
Cost of revenue 0  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [1] 7,861,477 7,368,623
Adjustments for expired and expiring inventory 0  
Depreciation and amortization (2) [2] 66,432 52,792
Loss from operations (3) [3] (7,927,909) (7,421,415)
Other expense, net (4) [4] (1,126,261) 345,524
Provision for income taxes   (9,690)
Net loss (9,054,170) (7,085,581)
Capital expenditures 8,436 25,218
Corporate Segment [Member] | UNITED STATES    
United States 3,817,195 6,326,031
Corporate Segment [Member] | Non-US [Member]    
United States 14,613 590
Royalty [Member]    
Revenue from Contract with Customer, Including Assessed Tax 14,645 0
Royalty [Member] | Diagnostics Segment [Member]    
Revenue from Contract with Customer, Including Assessed Tax   0
Royalty [Member] | Therapeutics Segment [Member]    
Revenue from Contract with Customer, Including Assessed Tax   0
Royalty [Member] | Corporate Segment [Member]    
Revenue from Contract with Customer, Including Assessed Tax   0
Sales Revenue [Member] | UNITED STATES    
Revenue from Contract with Customer, Including Assessed Tax 0  
Sales Revenue [Member] | Non-US [Member]    
Revenue from Contract with Customer, Including Assessed Tax 14,645  
Sales Revenue [Member] | Diagnostics Segment [Member]    
Revenue from Contract with Customer, Including Assessed Tax 14,645 0
Sales Revenue [Member] | Diagnostics Segment [Member] | UNITED STATES    
Revenue from Contract with Customer, Including Assessed Tax 0  
Sales Revenue [Member] | Diagnostics Segment [Member] | Non-US [Member]    
Revenue from Contract with Customer, Including Assessed Tax 14,645  
Sales Revenue [Member] | Therapeutics Segment [Member] | UNITED STATES    
Revenue from Contract with Customer, Including Assessed Tax 0  
Sales Revenue [Member] | Therapeutics Segment [Member] | Non-US [Member]    
Revenue from Contract with Customer, Including Assessed Tax 0  
Sales Revenue [Member] | Corporate Segment [Member] | UNITED STATES    
Revenue from Contract with Customer, Including Assessed Tax 0  
Sales Revenue [Member] | Corporate Segment [Member] | Non-US [Member]    
Revenue from Contract with Customer, Including Assessed Tax 0  
License [Member]    
Revenue from Contract with Customer, Including Assessed Tax $ 0 45,615
License [Member] | Diagnostics Segment [Member]    
Revenue from Contract with Customer, Including Assessed Tax   45,615
License [Member] | Therapeutics Segment [Member]    
Revenue from Contract with Customer, Including Assessed Tax   0
License [Member] | Corporate Segment [Member]    
Revenue from Contract with Customer, Including Assessed Tax   $ 0
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($95,819 and $76,954 for the years ended December 31, 2022 and 2021, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of gain on extinguishment of debt, interest income and interest expense, which are not currently allocated to our individual reportable segments.